Liquid Biopsy Test Helping Select People with Advanced Prostate Cancer for Phase 2 Study of Pamiparib
News
A Phase 2 trial testing the investigational PARP inhibitor pamiparib in treating metastatic castration-resistant prostate cancer patients is using Epic Sciences‘ novel liquid biopsy assay to select those patients who are ... Read more